Introduction and utilisation of high priced HCV medicines across Europe; implications for the future

• Main Authors: Winnie de Bruijn (Author), Cristina Ibáñez (Author), Pia Frisk (Author), Hanne Bak Pedersen (Author), Ali Alkan (Author), Patricia Vella Bonanno (Author), Ljiljana Sović Brkičić (Author), Anna Bucsics (Author), Guillame Dedet (Author), Jaran Eriksen (Author), Joseph O Fadare (Author), Jurij Fürst (Author), Gisselle Gallego (Author), Isabella Piassi Godói (Author), Augusto Afonso Guerra Junior (Author), Hakki Gürsöz (Author), Saira Jan (Author), Jan Jones (Author), Saim Kerman (Author), Roberta Joppi (Author), Ott Laius (Author), Newman Madzikwa (Author), Einar Magnusson (Author), Mojca Maticic (Author), Vanda Markovic-Pekovic (Author), Amos Massele (Author), Olayinka Ogunleye (Author), Aisling O'Leary (Author), Jutta Piessnegger (Author), Catherine Sermet (Author), Steven Simoens (Author), Celda Tiroyakgosi (Author), Ilse Truter (Author), Magnus Thyberg (Author), Kristina Tomekova (Author), Magdalene Wladysiuk (Author), Sortiris Vandoros (Author), Elif Hilal Vural (Author), Corinne Zara (Author), Brian Godman (Author)
• Format: Book
• Published: Frontiers Media S.A., 2016-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the proteas...